Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Conditions:   Breast Adenocarcinoma;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIB Breast CancerInterventions:   Drug: Tamoxifen Citrate;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Radiation: Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life AssessmentSponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   American College of Surgeons;   North Central Cancer Treatment Group;   Cancer and Leukemia Group B;   NSABP Foundation Inc;   NCIC Clinical Trials GroupActive, not recruiting - verified February 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conditions:   Breast Adenocarcinoma;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7 ;   Stage IIIC Breast Cancer AJCC v7 Interventions:   Biological: Pertuzumab;   Other: Place...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM Abstract PURPOSE: Amplifications of receptor tyrosine kinases (RTKS) are therapeutic targets in multiple tumor types (e.g. HER2 in breast cancer), and amplification of the chromosome 4 segment harboring the three RTKs KIT, PDGFRA, and KDR (4q12amp) may be similarly targetable. The presence of 4q12amp has been sporadically reported in small tumor specific series but a large-scale analysis is lacking. We assess the pan-cancer landscape of 4q12amp and provide early clinical support for the feasibility of targeting th...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
ConclusionsZW25 has been well tolerated with promising single agent activity in heavily pre-treated patients. These data support further clinical development of this bispecific antibody in HER2-expressing solid tumors.Clinical trial identificationNCT03929666.Legal entity responsible for the studyZymeworks, Inc.FundingZymeworks, Inc.DisclosureF. Meric-Bernstam: Research grant / Funding (institution): Novartis; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Taiho; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Calithera; Research grant ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Late recurrence of estrogen receptor (ER) positive breast cancer is common. When tissues from a recurrent or metastatic focus are available, re-evaluation of ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status is recommended for treatment selection. This case report describes a 59-year-old woman who underwent surgery for left breast cancer, with a histopathological diagnosis of invasive ductal carcinoma (pathological stage T2N1aM0 Stage IIB, ER positive, PgR positive and HER2 negative). A health check-up 16 years after surgery revealed multiple hepatic mass lesions, and the patient w...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Publication date: Available online 6 June 2019Source: The LancetAuthor(s): Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel Serin, Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-Lacourtoisie, Laurence Venat-Bouvet, Laurent Cany, Stéphanie Catala, David Khayat, Laetitia Gambotti, Iris PauportéSummaryBackgroundIn 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-...
Source: The Lancet - Category: General Medicine Source Type: research
In conclusion, our WGCNA analysis identified candidate prognostic biomarkers for further basic and clinical researches. Introduction Breast cancer is a frequently diagnosed malignancy and the leading cause of cancer death among females around the world, accounting for 24% of cancer diagnoses and 15% of cancer deaths in females. According to Global Cancer Statistics 2018, there will be nearly 2.1 million new cases diagnosed globally, with ~62 thousand deaths. The incident rates of breast cancer increased in most developing countries during last decades, resulting from a combination of social and economic factors, incl...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
This study aims to determine indicators of prognosis, including primary tumor resection, for stage IV IBC patients.MethodsUsing the National Cancer Data Base, female patients diagnosed 2010 –2013 with unilateral a priori metastatic T4d invasive adenocarcinoma of the breast were identified. We conducted propensity score matched analysis to balance confounders of surgery versus no-surgery. Stratified log-rank test and double-robust estimation under the Cox model were used to assess the effect of surgery, and margins, on overall survival (OS) in the propensity score matched cohort.ResultsOf 1266 patients, 41% underwent ...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Background: Residual breast cancer after NAC is associated with a high risk of recurrence. Little evidence supports the use of further chemotherapy in this setting. Eribulin, an inhibitor of microtubule dynamics, demonstrated a survival advantage in patients with metastatic breast cancer who had progressed after previous anthracycline and taxane therapy. This phase 2 trial assessed the efficacy of eribulin (2-yr disease-free survival) administered postoperatively to breast cancer pts not achieving a pCR following standard NAC.Methods: Women with invasive breast cancer (stage T1-4b, N0-2, M0 at diagnosis) and evidence of re...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Adenocarcinoma | Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Hormonal Therapy | Hormones | Research | Women